Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

ZeaChem (Lakewood, CO) a development-stage biofuels company focused on cellulose-based biorefinery processes for producing ethanol, closed a $24M Series C financing. Participants include Birchmere Ventures, Firelake Capital, Globespan Capital Partners, Mohr Davidow Ventures, PrairieGold Venture Partners and Spring Ventures.

Sera Prognostics (Salt Lake City, UT) a development-stage diagnostic company focused on preterm birth and other pregnancy complications, closed a $19.3M Series A financing. Participants include InterWest Partners, Domain Associates, Catalyst Health Ventures, UpStart Life Sciences Capital and Osage University Partners.

OPX Biotechnologies (Boulder, CO) a development-stage biofuels company using synthetic biology to engineer the microbes as a bio-acrylic renewable fuel source, closed a $36.5M Series C financing. Participants include US Renewables Group, DBL Investors, Mohr Davidow Ventures, Braemar Energy Ventures, Altira Group and X/Seed Capital. Thanx for your patience as we catch-up.

Surefire Medical (Westminster, CO) a development-stage medical device company focused on interventional radiology embolic agent delivery, closed a $6.1M Series A financing. Participants include Partisan Management Group and High Country Venture.

Mosaic Bioscience (Boulder, CO) a development-stage synthetic materials company focused on tissue and bone regeneration, closed a $1M Series A financing. Participants include Morgenthaler, HealthCare Ventures and High Country Venture.

Precision Biopsy (Aurora, CO) a development-stage diagnostics company focused on advanced spectroscopy imaging and tissue biopsy for the diagnosis of prostate cancer, closed a $2.5M Series A financing. Participants include Allied Minds.

PanTheryx (Boulder, CO) a commercial-stage pharmaceutical company focused on the acquisition, development and commercialization of pain, inflammation, GERD, rhinitis and peripheral neuropathy products for the Indian healthcare market, closed a $1M Series A financing. Participants were not identified.

Accera (Broomfield, CO) a commercial-stage biotechnology company that developed and markets Axona for the dietary management of metabolic processes associated with mild to moderate Alzheimer’s disease, closed a $11M Series D financing. Participants were not identified, prior investors have include Inventages Venture Capital, POSCO BioVentures and Bloodstone Ventures.

Biodesix (Broomfield, CO) a commercial-stage personalized medicine company focused on diagnostic products that inform treatment decisions and patient care, whose initial product, VeriStrat, predicts response to the targeted therapy erlotinib in patients with advanced NSCLC, closed a $7.1M Series C financing. Participants were not identified.

Lineagen (Salt Lake City, UT) a development stage content-based biomarker discovery company focused on diagnostic tests for autism, multiple sclerosis and COPD, closed a $5M Series A, bringing the total round to $10.8M. Participants include PrairieGold Venture Partners, vSpring Capital, Sanderling Ventures and Mesa Verde Venture Partners.

N30 Pharma (Boulder, CO) a preclinical-stage biopharmaceutical company focused on small molecules inhibting GSNOR for the potential treatment of asthma, COPD, inflammatory bowel disease and heart failure, closed a $10M Series B financing. Participants include Deerfield Management, Tiger Management, Bridger Capital and Swift Current Partners.

GlobeImmune (Lousiville, CO) a clinical-stage biopharmaceutical company developing a therapeutic vaccine platform focused on pancreatic cancer and hepatitis C, Closed a $17.5M Series E financing. Participants include Generali Financial Holding, BSI, Celgene, Wexford Capital, Mellon Family Investment Company, Eminent Venture Capital, Boston Life Science Venture, WRF Capital, Partners Healthcare, Yasuda, Genentech, Biogen Idec, CIDC, PAC-LINK […]

Coherex Medical (Salt Lake City, UT) a development-stage medical device company focused on the Flatstent™ EF PFO Closure System used to close patent foramen ovale heart defects, closed a $16.5M Series B financing. Participants include Oxford Bioscience Partners, vSpring Capital and Tullis Health Investors.

« Previous Entries  Next Page »

to top of page...